Keywords: Eli Lilly, Kowa, Livalo, LDL-C reduction, Cholesterol, PREVAIL US study
Lilly and Kowa's Livalo meets primary endpoint of LDL-C reduction
Article | 01 June 2012
Presenting at the National Lipid Association's (NLA) Scientific Sessions in Scottsdale, Arizona, USA, Kowa Pharmaceuticals America, a subsidiary of privately ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
